title: Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma.
abstract: B-lymphocyte stimulator (BLyS) plays a critical role in the survival of B-lymphocytes. In 50 patients with Hodgkin's lymphoma BLyS levels were higher in newly diagnosed patients (median 2.0 ng/mL, range <0.3-56.0) and relapsed patients (8.7 ng/mL, range 1.5-71.5) than in 93 healthy donors (<0.3 ng/mL, range <0.3-0.5). High serum BLyS levels (> or =2.0 ng/mL) in newly diagnosed patients were associated with resistance to therapy (p=0.01) and shorter progression-free survival (log-rank p=0.029, 2-year rate 64% vs 100%). Serum BLyS levels may have prognostic significance in Hodgkin's lymphoma.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Oki
authors.forename: Georgios V
authors.initials: GV
authors.lastname: Georgakis
authors.forename: Thi-Sau
authors.initials: TS
authors.lastname: Migone
authors.forename: Larry W
authors.initials: LW
authors.lastname: Kwak
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
mesh_terms: D000328:Adult; D053264:B-Cell Activating Factor / Q000097:blood* / Q000502:physiology*; D016022:Case-Control Studies; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000097:blood* / Q000175:diagnosis* / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D053264:B-Cell Activating Factor